

RESEARCH ARTICLE

Open Access



# The CO<sub>2</sub>-dependence of *Brucella ovis* and *Brucella abortus* biovars is caused by defective carbonic anhydrases

Lara Pérez-Etayo<sup>1</sup>, María Jesús de Miguel<sup>2</sup>, Raquel Conde-Álvarez<sup>1</sup>, Pilar M. Muñoz<sup>2</sup>, Mammam Khames<sup>3,4</sup>, Maite Iriarte<sup>1</sup>, Ignacio Moriyón<sup>1</sup> and Amaia Zúñiga-Ripa<sup>1\*</sup>

## Abstract

*Brucella* bacteria cause brucellosis, a major zoonosis whose control requires efficient diagnosis and vaccines. Identification of classical *Brucella* spp. has traditionally relied on phenotypic characterization, including surface antigens and 5–10% CO<sub>2</sub> necessity for growth (CO<sub>2</sub>-dependence), a trait of *Brucella ovis* and most *Brucella abortus* biovars 1–4 strains. Although molecular tests are replacing phenotypic methods, CO<sub>2</sub>-dependence remains of interest as it conditions isolation and propagation and reflects *Brucella* metabolism, an area of active research. Here, we investigated the connection of CO<sub>2</sub>-dependence and carbonic anhydrases (CA), the enzymes catalyzing the hydration of CO<sub>2</sub> to the bicarbonate used by anaplerotic and biosynthetic carboxylases. Based on the previous demonstration that *B. suis* carries two functional CAs (CAI and CAII), we analyzed the CA sequences of CO<sub>2</sub>-dependent and -independent brucellae and spontaneous mutants. The comparisons strongly suggested that CAII is not functional in CO<sub>2</sub>-dependent *B. abortus* and *B. ovis*, and that a modified CAII sequence explains the CO<sub>2</sub>-independent phenotype of spontaneous mutants. Then, by mutagenesis and heterologous plasmid complementation and chromosomal insertion we proved that CAI alone is enough to support CO<sub>2</sub>-independent growth of *B. suis* in rich media but not of *B. abortus* in rich media or *B. suis* in minimal media. Finally, we also found that insertion of a heterologous active CAII into *B. ovis* reverted the CO<sub>2</sub>-dependence but did not alter its virulence in the mouse model. These results allow a better understanding of central aspects of *Brucella* metabolism and, in the case of *B. ovis*, provide tools for large-scale production of diagnostic antigens and vaccines.

## Introduction

*Brucella* is a genus of gram-negative bacteria of the  $\alpha$ -2 subdivision of the class *Proteobacteria* [1] that includes the causal agents of brucellosis, a zoonosis producing important economical losses and human suffering in many developing countries [2]. Currently, the genus contains twelve nominal species often showing host preference. Those spp. that were identified early (frequently referred to as the classical *Brucella* spp.) are *Brucella abortus*, preferentially infecting cattle, *B. melitensis*, usually infecting sheep and goats, *B. suis*, infecting pigs,

hares, reindeer and several wild rodents, *B. canis*, found in dogs, *B. neotomae*, isolated from desert wood rats, and *Brucella ovis*, a non-zoonotic species that is restricted to sheep and causes a condition known as *B. ovis* ovine epididymitis [3]. More recently, brucellae have been isolated from marine mammals, voles and other wild life vertebrates, and new species proposed [4–8].

Conventional identification of the classical *Brucella* spp. and biovars has traditionally relied on dye and phage sensitivity, H<sub>2</sub>S production, urease activity, requirement of 5–10% CO<sub>2</sub> atmospheres (0.04% in normal air) for growth (CO<sub>2</sub>-dependence) and surface antigens [9]. Even though these methods are being rapidly replaced by molecular tests, antigenic structure and CO<sub>2</sub>-dependence remain of immediate practical interest as these properties affect the conditions for primary isolation and

\*Correspondence: [azuniga@unav.es](mailto:azuniga@unav.es)

<sup>1</sup> Instituto de Salud Tropical y Departamento de Microbiología y Parasitología-IDISNA, Universidad de Navarra, 31008 Pamplona, Spain  
Full list of author information is available at the end of the article



propagation in vitro and the implementation of diagnostic tests. Antigenically, the classical *Brucella* spp. are divided in two groups: the rough (R) species (*B. canis* and *B. ovis*), which carry R-type lipopolysaccharides (LPS), and the smooth (S) brucellae, which carry S-LPS [3, 10]. Concerning CO<sub>2</sub>-dependence, this is a trait of *B. ovis* and most strains of *B. abortus* biovars 1–4 [3, 10]. In both cases, CO<sub>2</sub>-independent variants may appear with low frequency [11] and, for obvious practical reasons, some of these variants have been used for *B. ovis* and *B. abortus* antigen production [3, 10]. Similarly, *B. abortus* vaccines have been developed on CO<sub>2</sub>-independent backgrounds [10].

The classical *Brucella* spp. are facultative intracellular parasites able to circumvent early proinflammatory responses and endowed with a type IV secretion system involved in the control of intracellular trafficking [12–15]. Moreover, it is postulated that these bacteria have progressively adapted their metabolism to the nutrients encountered within cells as an essential part of their intracellular strategy [16–21]. In this regard, despite being a notorious phenotype of practical importance, *Brucella* CO<sub>2</sub>-dependence has deserved no attention since the demonstration over 60 years ago that CO<sub>2</sub>-rich atmospheres are not required to reduce oxygen tension and that CO<sub>2</sub> is used as a nutrient per se (reviewed in [11]). Indeed, CO<sub>2</sub> assimilation requires carbonic anhydrases (CAs), a group of critically important ubiquitous enzymes distributed into six evolutionary distinct classes named  $\alpha$  to  $\eta$ , with the  $\beta$  class present in bacteria [22]. In heterotrophs, CAs are involved in C acquisition via assimilatory and anaplerotic reactions linked to several biosynthetic processes [23], and CO<sub>2</sub>-dependence has been related to defects in CA function in several microorganisms [24–30]. However, to the best of our knowledge, the role of CAs in CO<sub>2</sub>-dependence has not been investigated in *Brucella* spp. where the information is limited to recent investigations in search for targets for new drugs [31–34]. These investigations have described that *B. suis* (thus CO<sub>2</sub>-independent) strain 1330 has two ORFs (BRA0788 and BR1829) that code for  $\beta$  CAs (henceforth  $B_{s1330}$ CAI and  $B_{s1330}$ CAII). Both CAs are predicted to contain all the amino acid residues involved in the catalytic site and, more important, their activity was verified upon purification and found to be better for  $B_{s1330}$ CAII [31–33]. The demonstration that these *B. suis* ORFs actually code for enzymes with the predicted activity, together with the availability of the genome sequences of both CO<sub>2</sub>-independent and -dependent *Brucella* spp. and biovars, open the way to investigate the mechanisms underlying CO<sub>2</sub>-dependence in *Brucella*. The aim of the work described here was twofold: to investigate the genetic background behind the *Brucella*

CO<sub>2</sub>-independent and -dependent phenotypes and, for *B. ovis*, a species that shows constant CO<sub>2</sub>-dependence, to construct a CO<sub>2</sub>-independent strain suitable for vaccine and antigen production.

## Materials and methods

### Bacterial strains and growth conditions

The bacterial strains and plasmids used in this study are listed in Table 1 and Additional files 1 and 2. *B. abortus* and *B. suis* strains were grown in standard Peptone-Glucose (Tryptic soy broth, TSB) or in this medium supplemented with agar (TSA). *B. ovis* strains were grown in TSB supplemented with yeast extract (0.5%) and fetal bovine serum 5% (TYSB) or this medium supplemented with agar (TYSA). For the studies in mice, strains were grown in Blood Agar Base supplemented with fetal bovine serum 5% (BABS). In addition, two minimal media were used. The components for 1 L of the defined medium of Gerhardt (Glutamate–Lactate–Glycerol) [35] are: glycerol (30 g), lactic acid (5 g), glutamic acid (1.5 g), thiamine (0.2 mg), nicotinic acid (0.2 mg), pantothenic acid (0.04 mg), biotin (0.0001 mg), K<sub>2</sub>HPO<sub>4</sub> (10 g), Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>·5H<sub>2</sub>O (0.1 g), MgSO<sub>4</sub> (10 mg), MnSO<sub>4</sub> (0.1 mg), FeSO<sub>4</sub> (0.1 mg) and NaCl (7.5 g). The pH was adjusted to 6.8–7. The second minimal medium was a modification of Plommet's [17, 36] and 1 L of this medium is composed of thiamine (0.2 g), nicotinic acid (0.2 g), pantothenic acid (0.07 g), biotin (0.1 mg), K<sub>2</sub>HPO<sub>4</sub> (2.3 g), KH<sub>2</sub>PO<sub>4</sub> (3 g), Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (0.1 g), MgSO<sub>4</sub> (0.01 g), MnSO<sub>4</sub> (0.1 mg), FeSO<sub>4</sub> (0.1 mg); NaCl (5 g), (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> (0.5 g) and 1 g/L of glucose. Incubation was at 37 °C, with (5%) or without CO<sub>2</sub>. When needed, media were supplemented with 5% sucrose (Sigma), kanamycin (Km) at 50 µg/mL, nalidixic acid (Nal) at 25 µg/mL, polymyxin (Pmx) at 1.5 µg/mL, chloramphenicol (Cm) at 20 µg/mL, spectinomycin (Spc) at 100 µg/mL or ampicillin (Amp) at 100 µg/mL (all from Sigma). All strains were stored in skimmed milk or TYSB-DMSO at –80 °C.

### Sequence analyses

Genomic sequences of *B. suis* 1330, *B. suis* 513 (not annotated), *B. abortus* 544 (not annotated) and *B. abortus* 292 were obtained from the databases at National Center for Biotechnology Information (NCBI), Kyoto Encyclopedia of Genes and Genomes (KEGG) or The Broad Institute. The genomic sequence of *B. abortus* 2308W was obtained from the European Nucleotide Archive (ENA) and compared with its sibling 2308 sequence in KEGG. When genomic sequences were not available (*B. ovis* PA, *B. ovis* REO198, *B. abortus* AB0339, AB0339-CO<sub>2</sub><sup>mut</sup>, *B. abortus* AB0127, AB0127-CO<sub>2</sub><sup>mut</sup>, *B. abortus* AB0130, AB0130-CO<sub>2</sub><sup>mut</sup> and BoPA-CO<sub>2</sub><sup>mut</sup>) ORFs were PCR amplified and then sequenced. DNA sequencing was carried out by

**Table 1 Characteristics of the *Brucella* strains used in CO<sub>2</sub>-dependence studies**

Strain (biovar)	CO <sub>2</sub> -dependence	Other relevant characteristics	References (code)
Reference/collection strains			
<i>B. suis</i> 1330 (1)	–	Virulent; reference strain of biovar 1; ATCC 23444	[9]
<i>B. suis</i> 513 (5)	–	Virulent; reference strain of biovar 5; NCTC 11996	[9, 45, 61]
<i>B. abortus</i> 2308W (1)	–	Virulent; Wisconsin replicate of USDA challenge strain 2308	[45, 62]
<i>B. abortus</i> 544 (1)	+	Virulent; reference strain of biovar 1; ATCC 23448	[9]
<i>B. abortus</i> 292 (4)	+	Virulent; reference strain of biovar 4; ATCC 23451	[9]
<i>B. ovis</i> PA (n.a.) <sup>a</sup>	+	Virulent; challenge strain used in <i>B. ovis</i> vaccine studies.	[63–65]
<i>B. ovis</i> REO198 (n.a.) <sup>a</sup>	–	Attenuated; genome not sequenced; used for R antigen production for serodiagnosis of ovine epididymitis	[3, 66]
Field strains			
<i>B. abortus</i> AB0339 (1)	+	Cattle isolate	[44]
<i>B. abortus</i> AB0127 (3)	+	Cattle isolate	[44]
<i>B. abortus</i> AB0130 (3)	+	Cattle isolate	[44]
Spontaneous mutants			
BoPA-CO <sub>2</sub> <sup>mut</sup> (n.a.) <sup>a</sup>	–	<i>B. ovis</i> PA mutant isolated during routine work at CITA	This work (Ov-2357)
AB0339-CO <sub>2</sub> <sup>mut</sup> (1)	–	<i>B. abortus</i> mutant isolated during routine work at University of Navarra	This work (AZB250)
AB0127-CO <sub>2</sub> <sup>mut</sup> (3)	–	<i>B. abortus</i> mutant isolated during routine work at University of Navarra	This work (AZB251)
AB0130-CO <sub>2</sub> <sup>mut</sup> (3)	–	<i>B. abortus</i> mutant isolated during routine work at University of Navarra	This work (AZB252)

<sup>a</sup> n.a. not applicable (no biovars defined for *B. ovis*).

“Servicio de Secuenciación de CIMA (Centro de Investigación Médica Aplicada, Pamplona, Spain)”. Sequence alignments were performed with Clustal Omega.

### DNA manipulations

Plasmid and chromosomal DNA were extracted with QIAprep Spin Miniprep (Qiagen) and Ultraclean Microbial DNA Isolation kit (Mo Bio Laboratories), respectively. When needed, DNA was purified from agarose gels using QIAquick Gel Extraction Kit (Qiagen). Primers (Additional file 3) were synthesized by Sigma (Haverhill, United Kingdom). Restriction modification enzymes were used under the conditions recommended by the manufacturer.

### Construction of *B. abortus* 2308W and *B. suis* mutants by gene disruption

For the construction of the CAI mutants, an internal region of 323 bp was amplified with oligonucleotides CAI-F1-ins (5'-GAATTTCTATGGATCGGCTGTT-3') and CAI-R2-ins (5'-CGGTCTGCGTGT'TTCTAT-3'). The resulting fragment containing an internal region of the ORF was cloned into pCR2.1-TOPO<sup>®</sup> vector (Invitrogen) to generate plasmid pCR2.1<sub>Ba2308W</sub>CAI (Additional file 2) and then, sequenced to verify the insertion. After sequencing, this fragment was cloned into the *Bam*HI and *Xba*I sites of the suicide vector pJQKm [37]. The resulting plasmid pJQKm<sub>Ba2308W</sub>CAI (Additional file 2) was transformed into competent *E. coli* S17 λpir [38,

39] and transferred into *B. abortus* 2308W, *B. suis* 1330 and *B. suis* 513 by conjugation, where a single crossover led to disruption of the wild type locus. Integrative mutants were selected on a medium containing kanamycin and nalidixic acid or polymyxin and called *B. abortus* 2308W::pJQKm-CAI, *B. suis* 513::pJQKm-CAI and *B. suis* 1330::pJQKm-CAI (Additional file 1). Since the orientation of the insert in the pJQKm vector was known after sequencing, gene disruption was confirmed by detecting PCR products with primers CAI-Fw and M13Fw and primers CAI-Rv and M13Rv.

The CAII mutants were constructed in a similar way. A 302 bp internal fragment of CAII was amplified with oligonucleotides CAII-F1-Ins (5'-CAATGTGGCCAA TCTCATTC-3') and CAII-R2-ins (5'-GCGAATAGC GGATCGAAATA-3'). The resulting fragment was cloned into pCR2.1-TOPO<sup>®</sup> vector (Invitrogen) to generate plasmid pCR2.1<sub>Ba2308W</sub> CAII (Additional file 2), sequenced to verify the insertion and subsequently cloned into the *Bam*HI and *Xba*I sites of the suicide vector pJQKm [37]. The mutants were named *B. suis* 513::pJQKm-CAII and *B. suis* 1330::pJQKm-CAII (Additional file 1). Since the orientation of the insert in the pJQKm vector was known after sequencing, the site of the insertion was confirmed by independent PCR rounds with primers CAII-Fw and M13Fw, and primers CAII-Rv and M13Rv. After several attempts, no mutant in *B. abortus* 2308W CAII was obtained either under normal or CO<sub>2</sub>-enriched conditions.

### Selection of CO<sub>2</sub>-independent spontaneous mutants

To obtain CO<sub>2</sub>-independent spontaneous mutants from CO<sub>2</sub>-dependent bacteria, *B. ovis* PA and three *B. abortus* isolates (one biovar 1 and two biovar 3) were plated on TYSA or TSA and incubated at 37 °C without CO<sub>2</sub>. After 5 days, one colony was picked and the genes encoding CAI and CAII were PCR amplified using primers CAI-Fw and CAI-Rv, and CAII-Fw and CAII-Rv (see Additional file 3). DNA sequencing with these primers and CAI-F1-Sec and CAII-F1-Sec primers (Additional file 3) allowed identification of mutations by comparison with the nucleotide sequence of the parental CO<sub>2</sub>-dependent strains.

### Construction of the plasmid carrying CAII<sub>Ba2308W</sub> and introduction into *B. abortus* 292 and 544

For the construction of the expression plasmid encoding Ba2308W CAII oligonucleotides CAII-Fw-Gw (5'-GGGGAC AAGTTTGTACAAAAAAGCAGGCTTCCGCTGC CGTGTTTGAAATCA-3') and CAII-Rv-Gw (5'-GGG GACCACTTTGTACAAGAAAGCTGGGTCTCAAAG TTCAGGGCGTTTGA-3') that contain sequences *attB* (underlined) were used to amplify CAII and the promoter from *B. abortus* 2308W. The resulting PCR product was cloned into pDONR223 to generate plasmid pDONOR223<sub>Ba2308W</sub>CAII (Additional file 2). After sequence verification, the ORF encoding CAII was transferred from pDONOR223<sub>Ba2308W</sub>CAII to pRH001 [40]. The resulting plasmid, pRH001<sub>Ba2308W</sub>CAII (Additional file 2) was transformed into competent *E. coli* S17 λpir and introduced into *Brucella* strains by conjugation. The clones that had acquired the plasmid were selected by kanamycin resistance and confirmed by PCR using primers CAII-Fw-Gw and CAII-Rv-Gw, and M13F-M13R. The strains were called *B. abortus* 292 pRH001<sub>Ba2308W</sub>CAII and *B. abortus* 544 pRH001<sub>Ba2308W</sub>CAII (Additional file 1).

### Construction of miniTn7T-Km<sup>R</sup> plasmids carrying CAI or CAII and introduction into *Brucella* strains

Using DNA from *B. abortus* 2308W, oligonucleotides CAII-IF-F1 (5'-CCGGGCTGCAGGAATTCGCTG CCGTGTTTGAAATCA-3') and CAII-IF-R2 (5'-AGC TTCTCGAGGAATTTCAAAGTTCAGGGCGTTTGA A-3') amplified a 966 bp region containing CAII and the promoter region. This fragment was cloned into the linearized vector (*EcoRI*) pUC18R6KT-miniTn7T-Km<sup>R</sup> [41] using the In-Fusion HD Enzyme Premix (Clontech). The resulting plasmid was called pUC18R6KT-miniTn7T-Km<sup>R</sup><sub>Ba2308W</sub>CAII (Additional file 2) and transformed into *E. coli* PIR1 and subsequently to *E. coli* S17 λpir. Then, it was transferred into *Brucella* by a tetraparental conjugation [42]. The resulting constructs (*B. abortus* 292

Tn7<sub>Ba2308W</sub>CAII, *B. abortus* 544 Tn7<sub>Ba2308W</sub>CAII and *B. ovis* PA Tn7<sub>Ba2308W</sub>CAII; Additional file 1) were confirmed by PCR for the correct insertion and orientation of the mini-Tn7 between genes *glmS* and *recG*. Primers GlmS\_B (5'-GTCCTTATGGGAACGGACGT-3') and Ptn7-R (5'-CACAGCATAACTGGACTGATT-3') were used to confirm insertion downstream *glmS*; Ptn7-L (5'-ATTAGCTTACGACGCTACACCC-3') and RecG (5'-TATATCTGGCGAGCGATCC-3') insertion upstream *recG* and GlmS\_B and RecG presence of transposon.

Oligonucleotides CAI-IF-F1 (5'-CCGGGCTGCAGG AATTTGTGGAATTGCACCGACAC-3') and CAI-IF-R2 (5'-AGCTTCTCGAGGAATTCAATTATCTGCCG GTTGG-3') amplified a 987 bp fragment from *B. suis* 513 DNA containing CAI and the promoter. This fragment was subsequently cloned into the linearized vector (*EcoRI*) pUC18R6KT-miniTn7T-Km<sup>R</sup> using the In-Fusion HD Enzyme Premix (Clontech). The resulting plasmid was called pUC18R6KT-miniTn7T-Km<sup>R</sup><sub>Bs513</sub>CAI (Additional file 2) and was transformed into *E. coli* PIR1 and then to *E. coli* S17 λpir. After, the plasmid was introduced into the different *Brucella* strains by a tetraparental conjugation [42]. The strains were called *B. abortus* 2308W Tn7<sub>Bs513</sub>CAI, *B. abortus* 292 Tn7<sub>Bs513</sub>CAI and *B. abortus* 544 Tn7<sub>Bs513</sub>CAI. The insertion of the transposon was confirmed by PCR (see above and Additional file 3).

When necessary, constructs without kanamycin resistance cassette were obtained following the protocol set up by Martínez-Gómez et al. [43].

### Growth measurements

The strains were inoculated into 10 mL of TSB or TYSB in a 50 mL flask and incubated at 37 °C for 18 h with or without orbital shaking, in an atmosphere with 5% CO<sub>2</sub> in the case of CO<sub>2</sub>-dependent strains. Then, these bacteria were harvested by centrifugation, resuspended in 10 mL of the test medium at an optical density at 600 nm (OD<sub>600nm</sub>) of 0.1, and incubated under the same conditions for 18 h. These exponentially growing bacteria were harvested by centrifugation, resuspended at an OD<sub>600nm</sub> of 0.1 (equivalent to 0.05 readings in the Bioscreen apparatus) in the test medium in appropriate multiwell plates (200 μL/well) and cultivated in a Bioscreen C (Lab Systems) apparatus with continuous shaking at 37 °C. Absorbance values at 420–580 nm were automatically recorded at 30 min-intervals. All experiments were performed in triplicate. Controls with medium and no bacteria were included in all experiments.

### Studies in mice

Seven-week-old female BALB/c mice (Harlan Laboratories; Bicester, United Kingdom) were accommodated in the facilities of "Centro de Investigación y Tecnología



Agroalimentaria de Aragón" (CITA; Registration code ES502970012025) for 2 weeks before and during the experiments, with water and food ad libitum under P3 biosafety containment conditions. The animal handling and other procedures were in accordance with the current European (directive 86/609/EEC) and Spanish (RD 53/2013) legislations, supervised by the Animal Welfare Committee of the CITA (2014-20).

To prepare inocula, BABS-grown bacteria were harvested, adjusted spectrophotometrically ( $OD_{600nm} = 0.170$ ) in sterile buffered saline (BSS; 0.85% NaCl, 0.1%  $KH_2PO_4$ , 0.2%  $K_2HPO_4$ ; pH 6.85) and diluted in the same diluent up to approximately  $5 \times 10^7$  CFU/mL. For each bacterial strain, five mice were intraperitoneally inoculated with 0.1 mL/mouse, the exact doses assessed retrospectively by plating dilutions of the inocula. The number of CFU in spleen was determined at 3 and 8 weeks post-inoculation. For this, the spleens were aseptically removed and individually weighed and homogenized in 9 volumes of BSS. Serial tenfold dilutions of each homogenate were performed, and each dilution was plated by triplicate. Plates were incubated at 37 °C, without  $CO_2$ , for 5 days. The identity of the spleen isolates was confirmed by PCR. The individual number of CFU/spleen was normalized by logarithmic transformation, and the mean log CFU/spleen values and the standard deviations ( $n=5$ ) were calculated. Statistical comparisons were performed by Student's *t*-test.

## Results

### ORF sequences suggest a critical role of CAII in $CO_2$ -independence

We first analyzed whether the sequences of  $Bs_{1330}$ CAI and  $Bs_{1330}$ CAII, respectively encoded by BRA0788 and BR1829 of *B. suis* 1330 and with proved CA activity, had orthologues in reference and collection strains representative of the  $CO_2$ -independent and -dependent *Brucella* phenotypes (Table 1). This analysis showed that all these brucellae carry  $Bs_{1330}$ CAI and  $Bs_{1330}$ CAII orthologues, with the peculiarities summarized below (for further details, see Additional files 4 and 5).

*B. suis* 513  $Bs_{1330}$ CAI orthologue differed from  $Bs_{1330}$ CAI only at position 40 (serine instead of leucine) and carried a CAII identical to  $Bs_{1330}$ CAII. The *B. abortus* 2308W  $Bs_{1330}$ CAI orthologue differed from  $Bs_{1330}$ CAI in that the serine at position 40 and valine in position 76 were both substituted by glycine. Similarly, the  $Bs_{1330}$ CAII orthologue had an extra amino acid (alanine) at position 114. *B. abortus* 292 and 544, both  $CO_2$ -dependent, contained a  $Bs_{1330}$ CAI orthologue with the same serine and valine substitutions as strain 2308W, and a cytosine insertion at position 338 of the  $Bs_{1330}$ CAII orthologue leading to a frameshift affecting almost 50% of the protein. In the


*B. ovis* PA  $Bs_{1330}$ CAI orthologue, a deletion of 24 nucleotides at positions 217–240 results in a protein lacking amino acids 74–81, and the insertion of a guanine at the  $Bs_{1330}$ CAII orthologue originates a frameshift and a protein defective in the last 40 amino acids. *B. ovis* REO198, which is  $CO_2$ -independent, is identical to *B. ovis* PA with respect to the  $Bs_{1330}$ CAI orthologue. However, the lack of a guanine in the  $Bs_{1330}$ CAII orthologue three positions after the 521 position guanine of its *B. ovis* PA counterpart restores the reading frame and should allow synthesis of a protein identical to that of *B. suis* 1330 (Additional files 4 and 5). Altogether, the observations strongly suggest that the  $CO_2$ -dependence of *B. ovis* PA, *B. abortus* 292 and 544 is caused by the lack of an active CAII (activity defined empirically as that allowing growth in a normal atmosphere) and, conversely, that mutations in *B. ovis* CAII could account for the spontaneous emergence of  $CO_2$ -independent strains in at least *B. ovis*. On the other hand, these analyses did not allow inferring the relevance of CAI, which was apparently complete in *B. abortus* and *B. suis*.

### CAII is mutated in spontaneous $CO_2$ -independent mutants

We examined first the validity of the hypothesis on the relevance of CAII for growth in normal air by comparing the putative CA genes of several spontaneous  $CO_2$ -independent mutants that appeared during routine laboratory manipulations with their parental counterparts (Table 1). For the *B. ovis* PA  $CO_2$ -independent mutant (BoPA- $CO_2^{mut}$ ), we observed that while the guanine in the CAII gene causing the above-described frameshift was absent, the CAI gene had not undergone any changes. The  $CO_2$ -independent mutants of three recent *B. abortus* isolates (one biovar 1 and two biovar 3) [44] lacked a guanine at position 340 of the CAII gene that was however present in the  $CO_2$ -dependent parental isolates. Altogether, these results support the starting hypothesis that CAII mutations are involved in the emergence of  $CO_2$ -independent mutants and indirectly suggest that CAI is less relevant in the uptake of  $CO_2$ .

### An active CAI is enough by itself to support $CO_2$ -independent growth of *B. suis* but not of *B. abortus*

To compare the physiological importance of CAI and CAII we first carried out mutagenesis in different backgrounds and tested the mutants for  $CO_2$ -independence. Using *B. abortus* 2308W, we found that its CAI mutant (*B. abortus* 2308W::pJQKm-CAI) kept the  $CO_2$ -independent phenotype, proving that CAI by itself can sustain growth under normal atmospheric conditions (Figure 1). In contrast, and despite repeated attempts, we failed to obtain a similar mutant in CAII, suggesting that the *B. abortus* 2308W CAI cannot supply bicarbonate at





a rate high enough for growth under normal atmospheric conditions. This is in keeping with the identity of CAI sequence between *B. abortus* 2308W on one hand and *B. abortus* 292 and 544 on the other, and supports the idea that CAI is not active in these three *B. abortus* strains.

Köhler et al. [34] reported recently the failure to obtain *B. suis* 1330 (biovar 1) double CAI–CAII mutants, which together with the analysis of the purified CAI [31–33] strongly suggests that CAI is active in this strain. Thus, we

hypothesized that CAI could be inactive in some *Brucella* strains but active in others. Indeed, this possibility was consistent with the observation that the valine in position 76 in *B. suis* 1330<sub>Bs1330</sub>CAI was substituted by glycine in *B. abortus* 292 and 544 (both CO<sub>2</sub>-dependent) as well as in strain 2308W (see above and Additional file 4) where CAII seemed essential for CO<sub>2</sub>-independence. To validate our hypothesis, we first constructed pJQKm insertion mutants in the *Bs1330*CAI and *Bs1330*CAII genes of *B. suis* 1330 (biovar 1) and found that both were CO<sub>2</sub>-independent (Figure 2). Then, we obtained similar pJQKm insertion mutants in *B. suis* 513 (biovar 5). Again, both mutants kept the CO<sub>2</sub>-independent phenotype of the parental strain, proving that CAI was also active in *B. suis* 513 despite the difference in position 40 (serine instead of leucine) with respect to *Bs1330*CAI (see above and Additional files 4 and 5).

Once we knew that CAII was essential for CO<sub>2</sub>-independent growth of *B. abortus* 2308 W and that CAI was active in *B. suis* 1330 and 513, we tested whether a functional CAII or CAI could accomplish the same role in CO<sub>2</sub>-dependent *B. abortus* strains. For this, we first constructed a low-copy plasmid (pRH001<sub>Ba2308W</sub>CAII) carrying the gene encoding *B. abortus* 2308W CAII (which we had proven to be active) under the control of its own promoter. When we introduced this plasmid into *B. abortus* 292 and 544 (both CO<sub>2</sub>-dependent), the pRH001<sub>Ba2308W</sub>CAII constructs were able to grow in a normal atmosphere (Figure 3). Then, to circumvent any gene dosage artifacts associated with plasmid constructs, we introduced a miniTn7 carrying *Ba2308W*CAII (Tn7<sub>Ba2308W</sub>CAII) [42] into a neutral site of the genomes





of *B. abortus* 292 and 544. We found that, like the strain origin of the CAII gene, the two constructs grew in a normal atmosphere (Figure 3). Then, we did similar experiments with a miniTn7 carrying *Bs513*CAI (which we had proven to be active) and its promoter (Tn7<sub>Bs513</sub>CAI). In this case, however, we found that the *B. abortus* 292 and 544 Tn7<sub>Bs513</sub>CAI constructs failed to grow without CO<sub>2</sub> enrichment (data not shown) leading to the conclusion that an active CAI was not enough by itself to support CO<sub>2</sub>-independent growth of *B. abortus*.


**The CO<sub>2</sub>-independence mediated by CAI is conditioned by nutrient availability**

While the above-described experiments show that an active CAII but not an active CAI was enough to bypass CO<sub>2</sub>-dependence in *B. abortus*, it was not immediately obvious why CAI by itself was enough to support growth of *B. suis* 1330 and *B. suis* 513. However, the *B. suis* CAII (and CAI) mutants were tested for CO<sub>2</sub>-independence in a medium rich in peptones and glucose, conditions that are likely to downplay the role of the anabolic pathways where CA activity is important. Therefore, we reasoned that, depending upon the metabolic abilities of *Brucella* spp. and biovars, experiments in complex media could be not stringent enough to reveal differences between CAI and CAII activities. To analyze this, we took advantage of the almost prototrophic characteristics of *B. suis* 513, a strain that only requires a few vitamins and grows efficiently with limited C supplies [45]. When we tested *B. suis* 513::pJQKm-CAII insertion mutant on Glutamate-Lactate-Glycerol (a gluconeogenic medium [21, 45]) or


Glucose as the only C sources, we found that the mutant failed to grow under a normal atmosphere (Figure 4). This result, which shows that *B. suis* 513 CAI cannot meet the biosynthetic demands of this strain in simple media, strongly suggest that CAI is not active enough in less prototrophic species such as *B. abortus* even in complex media and, therefore, that it adds little to the role of CAII. In keeping with this, we found that a *B. abortus* 2308 W construct carrying *Bs513*CAI and its parental strain did not differ in growth rates (Figure 5).

**An active CAII reverts the CO<sub>2</sub>-dependence of *B. ovis* PA and does not alter its multiplication in the mouse model**

Among the brucellae, *B. ovis* is notorious for its CO<sub>2</sub>-dependence and fastidious nutritional requirements caused in all likelihood by its comparatively genome degradation [46]. Since the above-described experiments not only proved the chief role of CAII in the *B. abortus* and *B. suis* biovars tested but also provided molecular tools for relieving CO<sub>2</sub>-dependence in *B. abortus*, we introduced Tn7<sub>Ba2308W</sub>CAII into the *B. ovis* PA chromosome and examined the construct for CO<sub>2</sub>-dependence. As can be seen in Figure 6A, *B. ovis* PA Tn7<sub>Ba2308W</sub>CAII grew under normal atmospheric conditions. Then, we used the Tn7<sub>Ba2308W</sub>CAII construct to test whether the CO<sub>2</sub>-dependence and/or this genetic manipulation would alter the virulence of *B. ovis* in the standard mouse model. We found that the introduction of a functional CAII into *B. ovis* PA did not affect the multiplication (acute phase) and permanence (chronicity) of the bacteria in the spleens of BALB/c mouse (Figure 6B).



**Figure 4** The CO<sub>2</sub>-independence mediated by CAI is conditioned by nutrient availability. Growth of *B. suis* strain 513 and the CA insertion mutants (*B. suis* 513::pJQKm-CAI; *B. suis* 513::pJQKm-CAII) were tested under normal atmospheric conditions in Glutamate-Lactate-Glycerol and Glucose. Each point represents the mean ± standard error (error bars are within the size of the symbols) of technical triplicates. The experiment was repeated three times with similar results.



**Figure 5** Insertion of the gene of a functional CAI in *B. abortus* 2308W does not increase growth rates. Growth of *B. abortus* 2308W and its derivative strain carrying *B. suis* 513 CAI in the genome (*B. abortus* 2308W Tn7<sub>Bs513</sub>CAI) were tested under normal atmospheric conditions in Peptone-Glucose. Each point represents the mean ± standard error (error bars are within the size of the symbols) of technical triplicates. The experiment was repeated three times with similar results.


### Discussion

The metalloenzymes generically designated as CAs catalyze the reversible hydration of CO<sub>2</sub> into bicarbonate, the substrate of key anaplerotic and biosynthetic enzymes [23]. Many aerobic microorganisms can obtain enough bicarbonate from ambient air (about 0.04% CO<sub>2</sub>) and not surprisingly CA mutants of at least *Ralstonia eutropha*, *Streptococcus pneumoniae*, *Escherichia coli*,

*Pseudomonas aeruginosa* and *Corynebacterium glutamicum* are unable to grow under these conditions [25–30]. All these observations made very likely the existence of a relationship between CA deficiencies and the CO<sub>2</sub>-dependence that is characteristic of some *Brucella* biovars and species, a hypothesis proved in this work. If we define CA inactivity as that not high enough to make the bacteria able to grow in a normal atmosphere, we have demonstrated that while *B. suis* 1330 and 513 genomes encode two active CAs (CAI and CAII) only CAII is active in *B. abortus* 2308W and none in representative strains of the CO<sub>2</sub>-dependent *B. abortus* biovars or in *B. ovis* PA. Indeed, the fact that the gene encoding CAII is conserved in *B. abortus* 2308W is in agreement with previous in vitro enzymatic analysis that show that *B. suis* 1330 CAII is a better catalyst for the conversion of CO<sub>2</sub> to bicarbonate (with an enzymatic activity 1.85 times higher) than <sub>Bs1330</sub>CAI [32].

It has to be stressed that the functional definition of activity used here pertains to the particular physiology of each strain. Although the number of strains tested was necessarily limited, we found evidence supporting the hypothesis that CAI is insufficient to support growth of *Brucella* when the medium is limited to simple C substrates, or even in rich media for those brucellae that display comparatively reduced biosynthetic abilities. Indeed, whereas growth on the minimal media used here requires bicarbonate being incorporated by the reactions catalyzed by enzymes such as phosphoenolpyruvate carboxylase, pyruvate carboxylase, carbamoyl phosphate synthetase, 5-aminoimidazole ribotide carboxylase and





enoyl-CoA carboxylases/reductases, growth on rich media does not entail an intense biosynthesis of amino acids and nucleic acid precursors and, therefore, most if not all of the linked pathways should pose no stringent demands for bicarbonate. In the context of this hypothesis, *B. suis*, the fast-growing *B. suis* biovar 5 (strain 513) in particular, on one hand, and *B. ovis*, on the other, would respectively represent two opposite situations. The existence of *Brucella* strains carrying inactivated CAs strongly suggests that this enzymatic activity is not necessary for the persistency in nature of at least *B. abortus* and *B. ovis*. Indeed, the presence of mutations inactivating the metabolic genes may result from the absence of a positive selective pressure, reflecting an adaptation during which the cognate functions become dispensable because of the nutritional environment. Such a *Brucella* adaptation would not be a novelty in intracellular parasites because, while a majority of the genome-sequenced *Proteobacteria* retain a CA gene, intracellular genera such as *Buchnera* and *Rickettsia* contain CA-defective representatives [47]. It remains to be investigated whether such a CA dispensability represents a high CO<sub>2</sub> tension in their niche, as described for *Symbiobacterium thermophilum* [48], the exploitation of host CAs or the presence of nutrients bypassing metabolic steps connected to CA activity.

It is important to highlight the practical implications of this work. Unraveling the genetic background of *Brucella* CO<sub>2</sub>-dependence allowed us to construct a *B. ovis* CO<sub>2</sub>-independent mutant with practical implications on the diagnosis and control of *B. ovis* infection. Because of the non-zoonotic nature of *B. ovis*, this disease may not always deserve the attention of official programs and it is

often overlooked. Control and eventual eradication of *B. melitensis* brucellosis of small ruminants is based on the use of diagnostic tests detecting antibodies to the S-LPS [49] and vaccination with *B. melitensis* Rev 1, a vaccine that also protects against *B. ovis*. However, Rev 1 may interfere in serological diagnosis [49] and it is virulent for humans [50] and resistant to streptomycin (an antibiotic of choice to treat human brucellosis). Owing to these drawbacks, Rev 1 vaccination is discontinued and finally banned in those regions or countries where *B. melitensis* prevalence is considered low enough to implement an exclusively test and slaughter strategy. Withdrawal of Rev 1 vaccination leaves animals unprotected against *B. ovis*, thus favoring the emergence of the disease in areas where *B. melitensis* is almost or totally eradicated. Moreover, *B. ovis* has remained endemic in many areas where *B. melitensis* is not present and Rev 1 vaccination was never implemented [51, 52]. Accordingly, research on *B. ovis*-specific vaccines is an area of increasing interest as these vaccines would neither pose risk of zoonotic infection nor interfere in those *B. melitensis* serological tests detecting S-LPS O-polysaccharide antibodies (i.e., rose bengal and complement fixation tests) [53–56]. The CO<sub>2</sub> requirement represents a significant obstacle in the development of a *B. ovis* live attenuated vaccine for large-scale production. We have demonstrated that the *B. ovis* PA Tn7<sub>Ba2308W</sub>CAII described here not only grows under normal atmospheric conditions but also retains the virulence in at least the accepted laboratory model, thus representing an appropriate tool for the development of such CO<sub>2</sub>-independent attenuated vaccines. For instance, *B. ovis* PA Tn7<sub>Ba2308W</sub>CAII can be used as the

background to apply the strategy proposed by Conde-Álvarez et al. [57] based on the deletion of LPS core glycosyltransferases that results in a truncated structure that by uncovering innate immunity targets triggers a potent protective Th1 response. In fact, Soler-Lloréns et al. [56] recently demonstrated that deletion of two of such glycosyltransferases in *B. ovis* PA results in attenuation and suitable vaccine properties in the mouse model. Similarly, the *B. ovis* PA Tn7<sub>Ba2308W</sub>CAII construct could be used to produce the R-specific antigen currently used in *B. ovis* serological tests. This antigen is made of vesicles rich in outer membrane proteins and R-LPS, and both types of components have been shown to be important for optimal sensitivity [58, 59]. Currently, this R antigen is obtained from *B. ovis* REO198 taking advantage of the unusual CO<sub>2</sub>-independence of this strain (Table 1). Yet, *B. ovis* REO198 LPS carries a core oligosaccharide defect that damages the diagnostic epitopes of the R LPS and it is thus likely to yield suboptimal results in serodiagnosis [60]. If this is confirmed, it could be advantageously replaced by *B. ovis* PA Tn7<sub>Ba2308W</sub>CAII. Research is in progress to evaluate the attenuation and protection against *B. ovis* of *B. ovis* PA Tn7<sub>Ba2308W</sub>CAII core glycosyltransferase mutants as well as the diagnostic properties of R antigens obtained from this strain. In summary, the evidence presented in this work not only clarifies the biochemical basis of an important *Brucella* phenotype but also provides a tool for large-scale production of *B. ovis* diagnostic antigens and vaccines.

## Additional files

**Additional file 1.** Insertion mutants and genetic constructs obtained in this work.

**Additional file 2.** *E. coli* strains and plasmids.

**Additional file 3.** Primers.

**Additional file 4.** Structure-based sequence alignment of CAI. Gear symbols denote the residues observed as zinc ligands. The secondary structural features are indicated above the alignment (helices indicated as cylinders, strands as arrows). In bold, the six amino acid-sequence conserved in both CAI and CAII. Underlined, the glycine that has substituted the valine that is present in the *B. suis* strains.

**Additional file 5.** Structure-based sequence alignment of CAII. Gear symbols denote the residues observed as zinc ligands. The secondary structural features are indicated above the alignment (helices indicated as cylinders, strands as arrows). In bold the six amino acid-sequence conserved in both CAI and CAII.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

IM, MI and AZ-R conceived the study. LP-E, AZ-R, RC-Á, MK, MJM and PMM carried out the experimental work. IM, LP-E and AZ-R wrote the paper. All authors read and approved the final manuscript.

## Acknowledgements

The authors are grateful to F. J. Sangari and J. M. Blasco for helpful discussions and suggestions. The authors thank Sara Serrano and María Uriarte for excellent technical assistance.

## Funding

This research was supported by MINECO grant AGL2014-58795-C4-1-R (UNAV) and AGL2014-58795-C4-3-R (CITA), as well as by the Institute for Tropical Health funders (Obra Social La Caixa, Fundaciones Caja Navarra and Roviralta, PROFAND, Ubesol, ACUNSA and Artai). LP-E was supported by a grant from the Institute for Tropical Health. Work at CITA was sustained also by Aragon Government (Grupo de Investigación en Desarrollo A13-17D).

## Author details

<sup>1</sup> Instituto de Salud Tropical y Departamento de Microbiología y Parasitología-IDISNA, Universidad de Navarra, 31008 Pamplona, Spain. <sup>2</sup> Unidad de Producción y Sanidad Animal del Centro de Investigación y Tecnología Agroalimentaria de Aragón (CITA), Instituto Agroalimentario de Aragón (IA2), Zaragoza, Spain. <sup>3</sup> Department of Biology, University of Medea, 26000 Medea, Algeria. <sup>4</sup> National Veterinary High School, Algiers, Algeria.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 3 July 2018 Accepted: 3 August 2018

Published online: 05 September 2018

## References

- Moreno E, Stackebrandt E, Dorsch M, Wolters J, Busch M, Mayer H (1990) *Brucella abortus* 16S rRNA and lipid A reveal a phylogenetic relationship with members of the alpha-2 subdivision of the class *Proteobacteria*. *J Bacteriol* 172:3569–3576
- McDermott JJ, Grace D, Zinsstag J (2013) Economics of brucellosis impact and control in low-income countries. *Rev Sci Tech Off* 32:249–261
- OIE (2015) Ovine epididymitis (*Brucella ovis*). In: Manual of diagnostic tests and vaccines for terrestrial animals. Paris, pp 1–14
- Whatmore AM (2009) Current understanding of the genetic diversity of *Brucella*, an expanding genus of zoonotic pathogens. *Infect Genet Evol* 9:1168–1184
- Whatmore AM, Davison N, Cloeckaert A, Al Dahouk S, Zygmunt MS, Brew SD, Perrett LL, Koylass MS, Vergnaud G, Quance C, Scholz HC, Dick EJ, Hubbard G, Schlubritz-Loutsevitch NE (2014) *Brucella papionis* sp. nov., isolated from baboons (*Papio* spp.). *Int J Syst Evol Microbiol* 64:4120–4128
- Al Dahouk S, Köhler S, Occhialini A, Jiménez de Bagüés MP, Hammerl JA, Eisenberg T, Vergnaud G, Cloeckaert A, Zygmunt MS, Whatmore AM, Melzer F, Drees KP, Foster JT, Wattam AR, Scholz HC (2017) *Brucella* spp. of amphibians comprise genomically diverse motile strains competent for replication in macrophages and survival in mammalian hosts. *Sci Rep* 7:44420
- Scholz HC, Nockler K, Gollner C, Bahn P, Vergnaud G, Tomaso H, Al-Dahouk S, Kampfer P, Cloeckaert A, Marquart M, Zygmunt MS, Whatmore AM, Pfeffer M, Huber B, Busse HJ, De BK (2010) *Brucella inopinata* sp. nov., isolated from a breast implant infection. *Int J Syst Evol Microbiol* 60:801–808
- Scholz HC, Revilla-Fernández S, Al Dahouk S, Hammerl JA, Zygmunt MS, Cloeckaert A, Koylass M, Whatmore AM, Blom J, Vergnaud G, Witte A, Aistleitner K, Hofer E (2016) *Brucella vulpis* sp. Nov., isolated from mandibular lymph nodes of red foxes (*vulpes vulpes*). *Int J Syst Evol Microbiol* 66:2090–2098
- Alton GG, Jones LM, Angus RD, Verger J-M (1988) Techniques for the brucellosis laboratory. INRA, Paris
- OIE (2016) Brucellosis (*Brucella abortus*, *B. melitensis* and *B. suis*) (Infection with *B. abortus*, *B. melitensis* and *B. suis*). In: Manual of diagnostic tests and vaccines for terrestrial animals. Paris, pp 1–44
- Gerhardt P (1958) The nutrition of brucellae. *Bacteriol Rev* 22:81–98
- Barquero-Calvo E, Chaves-Olarte E, Weiss DS, Guzmán-Verri C, Chacón-Díaz C, Rucavado A, Moriyón I, Moreno E (2007) *Brucella abortus* uses a

- stealthy strategy to avoid activation of the innate immune system during the onset of infection. *PLoS One* 2:e631
13. Conde-Álvarez R, Arce-Gorvel V, Iriarte M, Manček-Keber M, Barquero-Calvo E, Palacios-Chaves L, Chacón-Díaz C, Chaves-Olarte E, Martirosyan A, von Bargen K, Grilló M-J, Jerala R, Brandenburg K, Llobet E, Bengoechea JA, Moreno E, Moriyón I, Gorvel J-P (2012) The lipopolysaccharide core of *Brucella abortus* acts as a shield against innate immunity recognition. *PLoS Pathog* 8:e1002675
  14. Palacios-Chaves L, Conde-Álvarez R, Gil-Ramírez Y, Zúñiga-Ripa A, Barquero-Calvo E, Chacón-Díaz C, Chaves-Olarte E, Arce-Gorvel V, Gorvel JPP, Moreno E, de Miguel MJ, Grilló MJ, Moriyón I, Iriarte M (2011) *Brucella abortus* ornithine lipids are dispensable outer membrane components devoid of a marked pathogen-associated molecular pattern. *PLoS One* 6:e16030
  15. Gorvel J-P, Moreno E (2002) *Brucella* intracellular life: from invasion to intracellular replication. *Vet Microbiol* 90:281–297
  16. Barbier T, Nicolas C, Letesson JJ (2011) *Brucella* adaptation and survival at the crossroad of metabolism and virulence. *FEBS Lett* 585:2929–2934
  17. Barbier T, Collard F, Zúñiga-Ripa A, Moriyón I, Becker J, Wittmann C, Van Schaftingen E, Letesson J-J (2014) Erythritol feeds the pentose phosphate pathway via three new isomerases leading to D-erythrose-4-phosphate in *Brucella*. *Proc Natl Acad Sci U S A* 111:17815–17820
  18. Barbier T, Machelart A, Zúñiga-Ripa A, Plovier H, Hougardy C, Lobet E, Willemart K, Muraille E, De Bolle X, Van Schaftingen E, Moriyón I, Letesson J-J (2017) Erythritol availability in bovine, murine and human models highlights a potential role for the host aldose reductase during *Brucella* infection. *Front Microbiol* 8:1088
  19. Letesson J-J, Barbier T, Zúñiga-Ripa A, Godfroid J, De Bolle X, Moriyón I (2017) *Brucella* genital tropism: what's on the menu. *Front Microbiol* 8:506
  20. Ronneau S, Moussa S, Barbier T, Conde-Álvarez R, Zúñiga-Ripa A, Moriyón I, Letesson J-J, Zuniga-ripa A, Moriyón I, Letesson J-J, Ronneau S, Moussa S, Barbier T, Conde-Álvarez R, Zúñiga-Ripa A (2014) *Brucella*, nitrogen and virulence. *Crit Rev Microbiol* 7828:1–19
  21. Zúñiga-Ripa A, Barbier T, Conde-Álvarez R, Martínez-Gómez E, Palacios-Chaves L, Gil-Ramírez Y, Grilló MJ, Letesson J-J, Iriarte M, Moriyón I (2014) *Brucella abortus* depends on pyruvate phosphate dikinase and malic enzyme but not on Fbp and GlpX fructose-1,6-bisphosphatases for full virulence in laboratory models. *J Bacteriol* 196:3045–3057
  22. Supuran CT (2016) Structure and function of carbonic anhydrases. *Biochem J* 473:2023–2032
  23. Erb TJ (2011) Carboxylases in natural and synthetic microbial pathways. *Appl Environ Microbiol* 77:8466–8477
  24. Aguilera J, Van Dijken JP, De Winde JH, Pronk JT (2005) Carbonic anhydrase (Nce103p): an essential biosynthetic enzyme for growth of *Saccharomyces cerevisiae* at atmospheric carbon dioxide pressure. *Biochem J* 391:311–316
  25. Hashimoto M, Kato J (2003) Indispensability of the *Escherichia coli* carbonic anhydrases YafF and CynT in cell proliferation at a low CO<sub>2</sub> partial pressure. *Biosci Biotechnol Biochem* 67:919–922
  26. Kusian B, Su D, Bowien B, Sültemeyer D (2002) Carbonic anhydrase is essential for growth of *Ralstonia eutropha* at ambient CO<sub>2</sub> concentrations. *J Bacteriol* 184:5018–5026
  27. Merlin C, Masters M, Mcateer S, Coulson A (2003) Why is carbonic anhydrase essential to *Escherichia coli*? *J Bacteriol* 185:6415–6424
  28. Mitsuhashi S, Ohnishi J, Hayashi M, Ikeda M (2004) A gene homologous to  $\beta$ -type carbonic anhydrase is essential for the growth of *Corynebacterium glutamicum* under atmospheric conditions. *Appl Microbiol Biotechnol* 63:592–601
  29. Burghout P, Cron LE, Gradstedt H, Quintero B, Simonetti E, Bijlsma JJE, Bootsma HJ, Hermans PWM (2010) Carbonic anhydrase is essential for *Streptococcus pneumoniae* growth in environmental ambient air. *J Bacteriol* 192:4054–4062
  30. Lotlikar SR, Hnatusk S, Dickenson NE, Choudhari SP, Picking WL, Patrauchan MA (2013) Three functional  $\beta$ -carbonic anhydrases in *Pseudomonas aeruginosa* PAO1: role in survival in ambient air. *Microbiology* 159:1748–1759
  31. Joseph P, Turtaut F, Ouahrani-Bettache S, Montero J-L, Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Köhler S, Winum J-Y, Supuran CT (2010) Cloning, characterization, and inhibition studies of a  $\beta$ -carbonic anhydrase from *Brucella suis*. *J Med Chem* 53:2277–2285
  32. Joseph P, Ouahrani-Bettache S, Montero JL, Nishimori I, Minakuchi T, Vullo D, Scozzafava A, Winum JY, Köhler S, Supuran CT (2011) A new  $\beta$ -carbonic anhydrase from *Brucella suis*, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth. *Bioorg Med Chem* 19:1172–1178
  33. Winum J-Y, Köhler S, Supuran CT (2010) *Brucella* carbonic anhydrases: new targets for designing anti-infective agents. *Curr Pharm Des* 16:3310–3316
  34. Köhler S, Ouahrani-Bettache S, Winum J (2017) *Brucella suis* carbonic anhydrases and their inhibitors: towards alternative antibiotics? *J Enzyme Inhib Med Chem* 32:683–687
  35. Gerhardt P, Wilson JB (1948) The nutrition of brucellae: growth in simple chemically defined media. *J Bacteriol* 56:17–24
  36. Plommet M (1991) Minimal requirements for growth of *Brucella suis* and other *Brucella* species. *Zentralbl Bakteriol* 275:436–450
  37. Scupham AJ, Triplett EW (1997) Isolation and characterization of the UDP-glucose 4'-epimerase-encoding gene, *galE*, from *Brucella abortus* 2308. *Gene* 202:53–59
  38. Simon R, Priefer U, Pühler A (1983) A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in gram negative bacteria. *Nat Biotechnol* 1:784–791
  39. Miller VL, Mekalanos JJ (1988) A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in *Vibrio cholerae* requires *toxR*. *J Bacteriol* 170:2575–2583
  40. Hallez R, Letesson J-J, Vandenhaute J, de Bolle X (2007) Gateway-based destination vectors for functional analyses of bacterial ORFeomes: application to the min system in *Brucella abortus*. *Appl Environ Microbiol* 73:1375–1379
  41. Llobet E, March C, Giménez P, Bengoechea JA (2009) *Klebsiella pneumoniae* OmpA confers resistance to antimicrobial peptides. *Antimicrob Agents Chemother* 53:298–302
  42. Choi KH, Gaynor JB, White KG, Lopez C, Bosio CM, Karkhoff-Schweizer RR, Schweizer HP (2005) A Tn7-based broad-range bacterial cloning and expression system. *Nat Methods* 2:443–448
  43. Martínez-Gómez E, Stähle J, Gil-Ramírez Y, Zúñiga-Ripa A, Zaccheus M, Moriyón I, Iriarte M, Widmalm G, Conde-Álvarez R (2018) Genomic insertion of a heterologous acetyltransferase generates a new lipopolysaccharide antigenic structure in *Brucella abortus* and *Brucella melitensis*. *Front Microbiol* 9:1092
  44. Khames M, Mick V, de Miguel MJ, Girault G, Conde-Álvarez R, Khelef D, Oumouna M, Moriyón I, Muñoz PM, Zúñiga-Ripa A (2017) The characterization of *Brucella* strains isolated from cattle in Algeria reveals the existence of a *B. abortus* lineage distinct from European and Sub-Saharan Africa strains. *Vet Microbiol* 211:124–128
  45. Zúñiga-Ripa A, Barbier T, Lázaro-Antón L, de Miguel MJ, Conde-Álvarez R, Muñoz PM, Letesson JJ, Iriarte M, Moriyón I (2018) The fast-growing *Brucella suis* biovar 5 depends on phosphoenolpyruvate carboxykinase and pyruvate phosphate dikinase but not on Fbp and GlpX fructose-1,6-bisphosphatases or isocitrate lyase for full virulence in laboratory models. *Front Microbiol* 9:641
  46. Tsolis RM, Seshadri R, Santos RL, Sangari FJ, Lobo JM, de Jong MF, Ren Q, Myers G, Brinkac LM, Nelson WC, Deboy RT, Angiuoli S, Khouri H, Dimitrov G, Robinson JR, Mulligan S, Walker RL, Elzer PEH, Hassan KA, Paulsen IT (2009) Genome degradation in *Brucella ovis* corresponds with narrowing of its host range and tissue tropism. *PLoS One* 4:e5519
  47. Ueda K, Nishida H, Beppu T (2012) Dispensabilities of carbonic anhydrase in proteobacteria. *Int J Evol Biol* 2012:324549
  48. Nishida H, Beppu T, Ueda K (2009) *Symbiobacterium* lost carbonic anhydrase in the course of evolution. *J Mol Evol* 68:90–96
  49. Ducrottoy MJ, Conde-Álvarez R, Blasco JM, Moriyón I (2016) A review of the basis of the immunological diagnosis of ruminant brucellosis. *Vet Immunol Immunopathol* 17:81–102
  50. Blasco JM, Díaz R (1993) *Brucella melitensis* Rev-1 vaccine as a cause of human brucellosis. *Lancet* 342:805
  51. Blasco JM (1997) A review of the use of *B. melitensis* Rev 1 vaccine in adult sheep and goats. *Prev Vet Med* 31:275–283
  52. Agence française de sécurité sanitaire des aliments (2008) Avis de l'Agence française de sécurité sanitaire des aliments sur un protocole de lutte contre l'épidémiologie contagieuse ovine (*Brucella ovis*) dans les Pyrénées-Atlantiques

53. Da Costa Martins R, Irache JM, Gamazo C (2012) Acellular vaccines for ovine brucellosis: a safer alternative against a worldwide disease. *Expert Rev Vaccines* 11:87–95
54. Moriyón I, Grilló MJ, Monreal D, González D, Marín CM, López-Goñi I, Mainar-Jaime RC, Moreno E, Blasco JM (2004) Rough vaccines in animal brucellosis: structural and genetic basis and present status. *Vet Res* 35:1–38
55. Silva APC, Macêdo AA, Costa LF, Turchetti AP, Bull V, Pessoa MS, Araújo MSS, Nascimento EF, Martins-Filho OA, Paixão TA, Santos RL (2013) *Brucella ovis* lacking a species-specific putative ATP-binding cassette transporter is attenuated but immunogenic in rams. *Vet Microbiol* 167:546–553
56. Soler-Lloréns P, Gil-Ramírez Y, Zabalza-Baranguá A, Iriarte M, Conde-Álvarez R, Zúñiga-Ripa A, San Román B, Zygmunt MS, Vizcaíno N, Cloeckaert A, Grilló M-J, Moriyón I, López-Goñi I (2014) Mutants in the lipopolysaccharide of *Brucella ovis* are attenuated and protect against *B. ovis* infection in mice. *Vet Res* 45:72
57. Conde-Álvarez R, Arce-Gorvel V, Gil-Ramírez Y, Iriarte M, Grilló MJ, Gorvel JP, Moriyón I (2013) Lipopolysaccharide as a target for brucellosis vaccine design. *Microb Pathog* 58:29–34
58. Riezu-Boj JI, Moriyón I, Blasco JM, Marín CM, Díaz R (1986) Comparison of lipopolysaccharide and outer membrane protein-lipopolysaccharide extracts in an enzyme-linked immunosorbent assay for the diagnosis of *Brucella ovis* infection. *J Clin Microbiol* 23:938–942
59. Riezu-Boj JI, Moriyón I, Blasco JM, Gamazo C, Díaz R (1990) Antibody response to *Brucella ovis* outer membrane proteins in ovine brucellosis. *Infect Immun* 58:489–494
60. Soler-Lloréns P (2014) Desarrollo de nuevas vacunas frente a *Brucella ovis*: Estudio de genes implicados en la síntesis del núcleo del lipopolisacárido. University of Navarra, Navarra
61. Vershilova PA, Lyamkin GI, Malikov VE, Dranovskaia EA (1983) *Brucella* strains from mouse like rodents isolated in the USSR. *Int J Syst Bacteriol* 33:399–400
62. Suárez-Esquivel M, Ruiz-Villalobos N, Castillo-Zeledón A, Jiménez-Rojas C, Roop RM II, Comerci DJ, Barquero-Calvo E, Chacón-Díaz C, Caswell CC, Baker KS, Chaves-Olarte E, Thomson NR, Moreno E, Letesson JJ, De Bolle X, Guzmán-Verrí C (2016) *Brucella abortus* strain 2308 wisconsin genome: importance of the definition of reference strains. *Front Microbiol* 7:1557
63. Blasco JM, Marín CM, Barberán M, Moriyón I, Díaz R (1987) Immunization with *Brucella melitensis* Rev 1 against *Brucella ovis* infection of rams. *Vet Microbiol* 14:381–392
64. Fensterbank R, Pardon P, Marly J (1982) Efficacy of *Brucella melitensis* Rev. 1 vaccine against *Brucella ovis* infection in rams. *Ann Rech Vet* 13:185–190
65. Blasco JM, Gamazo C, Winter AJ, Jiménez de Bagüés MP, Marín CM, Barberán M, Moriyón I, Alonso-Urmeneta B, Díaz R (1993) Evaluation of whole cell and subcellular vaccines against *Brucella ovis* in rams. *Vet Immunol Immunopathol* 37:257–270
66. Díaz R, Jones LM, Wilson JB (1968) Antigenic relationship of the gram-negative organism causing canine abortion to smooth and rough brucellae. *J Bacteriol* 95:618–624

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

